MCID: ADN027
MIFTS: 55

Adenomyosis

Categories: Muscle diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Adenomyosis

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 57 12 75 53 44 15 17
Endometriosis of Uterus 12 15 72 33
Endometriosis of Myometrium 12
Endometriosis, Myometrium 12
Endometriosis Interna 12
Uterine Adenomyosis 12

Characteristics:

OMIM:

57
Inheritance:
autosomal vs. x-linked dominant



Classifications:



External Ids:

Disease Ontology 12 DOID:288
OMIM 57 600458
ICD9CM 35 617.0
MeSH 44 D062788
NCIt 50 C6996
SNOMED-CT 68 76376003
ICD10 33 N80.0
MedGen 42 C0341858
UMLS 72 C0341858

Summaries for Adenomyosis

NIH Rare Diseases : 53 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to uterine anomalies and progesterone resistance. An important gene associated with Adenomyosis is PGR (Progesterone Receptor), and among its related pathways/superpathways are GPCR Pathway and Nanog in Mammalian ESC Pluripotency. The drugs Acetaminophen and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include uterus, pituitary and breast, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : 12 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM : 57 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 75 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 297, show less)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 32.1 VEGFA PGR ESR1 CYP19A1 CDH1
2 progesterone resistance 30.9 PGR ESR1
3 endometrial adenocarcinoma 30.9 VEGFA PGR HOXA10 ESR1
4 in situ carcinoma 30.7 PGR ESR1 CDH1
5 endometriosis of ovary 30.7 PGR HOXA10 ESR1 CYP19A1
6 endometrial disease 30.6 PTGS2 ESR1 CYP19A1
7 female reproductive endometrioid cancer 30.4 PGR ESR1
8 leiomyomatosis 30.4 PGR GNRH1 ESR1
9 intravenous leiomyomatosis 30.3 MME ESR1
10 adenosarcoma 30.2 PGR MME ESR1
11 myoma 30.2 PGR HOXA10 GNRH1 ESR1 CYP19A1
12 tubular adenocarcinoma 30.2 PGR ESR1 CDH1
13 endometriosis 30.1 VEGFA PTGS2 PGR HOXA10 GNRH1 ESR1
14 leiomyoma 30.0 PGR MME GNRH1 ESR1 CYP19A1
15 endometrial stromal sarcoma 30.0 PGR MME ESR1 CYP19A1
16 estrogen excess 29.9 PRL PGR ESR1 CYP19A1
17 ovarian hyperstimulation syndrome 29.9 VEGFA GNRH1 CYP19A1
18 smooth muscle tumor 29.7 PGR MME ESR1
19 uterine sarcoma 29.6 MME ESR1 CYP19A1
20 polycystic ovary syndrome 29.6 PRL GNRH1 CYP19A1
21 breast fibroadenoma 29.3 PGR MME ESR1 CYP19A1
22 uterine carcinosarcoma 29.3 PTGS2 PGR MME CDH1
23 ovarian cancer 28.2 VEGFA TIMP2 PGR MMP9 MMP2 GNRH1
24 endometrial cancer 26.9 VEGFA TIMP2 PGR MMP9 MMP2 MME
25 bartholin's gland adenoma 10.8 PGR ESR1
26 vestibular gland benign neoplasm 10.7 PGR ESR1
27 lung leiomyoma 10.7 PGR ESR1
28 extracranial arteriovenous malformation 10.7 MMP9 MMP2
29 vulvar syringoma 10.7 PGR ESR1
30 glassy cell carcinoma of the cervix 10.7 PGR ESR1
31 focal myositis 10.7 MMP9 MMP2
32 vulvar leiomyoma 10.7 PGR ESR1
33 trigonitis 10.7 PGR ESR1
34 vulvar benign neoplasm 10.7 PGR ESR1
35 villous adenocarcinoma 10.7 MMP9 MMP2
36 lentigo maligna melanoma 10.7 MMP9 MMP2
37 spastic entropion 10.7 MMP9 MMP2
38 infertility 10.7
39 predominantly cortical thymoma 10.7 PGR ESR1
40 breast scirrhous carcinoma 10.7 PGR ESR1
41 breast medullary carcinoma 10.7 PGR ESR1
42 angiokeratoma circumscriptum 10.7 VEGFA MMP9
43 oncocytic breast carcinoma 10.7 PGR ESR1
44 acute transverse myelitis 10.7 MMP9 MMP2
45 bartholin's gland benign neoplasm 10.7 PGR ESR1
46 senile ectropion 10.7 MMP9 MMP2
47 cribriform carcinoma 10.6 PGR ESR1
48 endometrial squamous cell carcinoma 10.6 PGR ESR1
49 internal hemorrhoid 10.6 MMP9 MMP2
50 adenomyoma 10.6
51 apocrine adenocarcinoma 10.6 PGR ESR1
52 adenoid basal cell carcinoma 10.6 PGR ESR1
53 adenocarcinoma 10.6
54 endometrial mucinous adenocarcinoma 10.6 PGR ESR1
55 myofibroma 10.6
56 intracystic papillary adenoma 10.6 PRL PGR
57 pancreatic serous cystadenoma 10.6 VEGFA PGR
58 synchronous bilateral breast carcinoma 10.6 PGR ESR1
59 gingival hypertrophy 10.6 TIMP2 MMP9
60 diffuse peritoneal leiomyomatosis 10.6 PGR ESR1
61 deep angioma 10.6 PGR ESR1
62 ischemic colitis 10.6 VEGFA MMP9 MMP2
63 benign metastasizing leiomyoma 10.6 PGR CYP19A1
64 odontogenic myxoma 10.6 VEGFA MMP9 MMP2
65 serous cystadenocarcinoma 10.6 VEGFA PGR MMP2
66 peritoneal benign neoplasm 10.6 PGR ESR1
67 fallopian tube carcinoma 10.5 VEGFA PGR ESR1
68 breast adenoid cystic carcinoma 10.5 PGR ESR1
69 breast carcinoma in situ 10.5 VEGFA PGR ESR1
70 grade iii astrocytoma 10.5 VEGFA MMP9 MMP2
71 adamantinous craniopharyngioma 10.5 VEGFA MMP9
72 microcystic meningioma 10.5 VEGFA TIMP2 MMP2
73 lymphangioleiomyomatosis 10.5 PGR MMP2 ESR1
74 endometrial hyperplasia 10.5
75 sick building syndrome 10.5 VEGFA MMP9
76 tuberculum sellae meningioma 10.5 PRL PGR
77 leiomyoma, uterine 10.5
78 amenorrhea 10.5
79 nasal cavity squamous cell carcinoma 10.5 TIMP2 MMP9 MMP2
80 adhesions of uterus 10.5 HOXA10 ESR1
81 light chain deposition disease 10.5 MMP9 MMP2
82 fungal keratitis 10.5 TIMP2 MMP9
83 cervical adenocarcinoma 10.5 PTGS2 PGR ESR1
84 progesterone-receptor positive breast cancer 10.5 PGR ESR1 CYP19A1
85 gender identity disorder 10.5 PGR ESR1 CYP19A1
86 sella turcica neoplasm 10.5 PRL PGR
87 aortic aneurysm, familial abdominal, 1 10.5 TIMP2 MMP9 MMP2
88 prostatic hypertrophy 10.4 PGR ESR1 CYP19A1
89 extrapelvic endometriosis 10.4
90 inguinal hernia 10.4 TIMP2 MMP9 MMP2
91 breast adenocarcinoma 10.4 MMP9 MMP2 ESR1
92 estrogen-receptor positive breast cancer 10.4 PGR ESR1 CYP19A1
93 microvascular complications of diabetes 1 10.4 VEGFA TIMP2 MMP9
94 conjunctival nevus 10.4 NGF MMP9 MMP2
95 corneal ulcer 10.4 NGF MMP9 MMP2
96 enhanced s-cone syndrome 10.4
97 ovarian cyst 10.4
98 postpartum depression 10.4 PRL OXTR ESR1
99 prolactin producing pituitary tumor 10.4 PRL NGF
100 balanitis xerotica obliterans 10.3 VEGFA PTGS2
101 ectopic pregnancy 10.3
102 cervix uteri carcinoma in situ 10.3
103 cervical intraepithelial neoplasia 10.3
104 ovarian cancer 1 10.3 VEGFA MMP2 CDH1
105 inflammatory breast carcinoma 10.3 PGR ESR1 CDH1
106 lipid-rich carcinoma 10.3 PGR ESR1 CDH1
107 laryngeal disease 10.3 MMP9 MMP2 CDH1
108 varicose veins 10.3 VEGFA TIMP2 MMP9 MMP2
109 pre-malignant neoplasm 10.3 PGR ESR1 CDH1
110 glycogen-rich clear cell breast carcinoma 10.3 PGR ESR1
111 nasopharyngeal disease 10.3 VEGFA MMP9 CDH1
112 hyperprolactinemia 10.3
113 pharynx cancer 10.3 VEGFA MMP9 CDH1
114 juvenile nasopharyngeal angiofibroma 10.3 VEGFA PGR ESR1 CYP19A1
115 tongue cancer 10.2 MMP9 MMP2 CDH1
116 oral submucous fibrosis 10.2 PTGS2 MMP2 CDH1
117 pituitary infarct 10.2 PRL GNRH1
118 chiasmal syndrome 10.2 PRL GNRH1
119 breast ductal carcinoma 10.2 PGR ESR1 CDH1
120 disseminated intravascular coagulation 10.2
121 leiomyosarcoma 10.2
122 nervous system disease 10.2 VEGFA NGF MMP9
123 tongue squamous cell carcinoma 10.2 MMP9 MMP2 CDH1
124 colorectal adenocarcinoma 10.2 VEGFA PTGS2 CDH1
125 respiratory system disease 10.2 VEGFA MMP9 CDH1
126 hypogonadotropism 10.2 PRL GNRH1
127 fibrosarcoma 10.2 TIMP2 MMP9 MMP2
128 hypothalamic disease 10.2 PRL GNRH1
129 breast myofibroblastoma 10.2 MME ESR1
130 intestinal disease 10.2 VEGFA PTGS2 CDH1
131 preterm premature rupture of the membranes 10.2
132 pre-eclampsia 10.2
133 vaginal discharge 10.2
134 placenta disease 10.2
135 uterine benign neoplasm 10.2 PGR GNRH1 ESR1
136 intramuscular hemangioma 10.2 PGR ESR1
137 myxoid leiomyosarcoma 10.1 PGR MME
138 pituitary apoplexy 10.1 PRL GNRH1
139 suppressor of tumorigenicity 3 10.1
140 mycobacterium tuberculosis 1 10.1
141 endometritis 10.1
142 endocarditis 10.1
143 iron metabolism disease 10.1
144 47,xyy 10.1
145 cytokine deficiency 10.1
146 mullerian aplasia 10.1
147 mammographic density 10.1 PRL PGR ESR1 CYP19A1
148 hypothyroidism, central, and testicular enlargement 10.1 PRL HOXA10 CYP19A1
149 gynecomastia 10.1 PRL PGR ESR1 CYP19A1
150 benign breast phyllodes tumor 10.1 PGR MME
151 aromatase deficiency 10.1 GNRH1 ESR1 CYP19A1
152 respiratory system cancer 10.1 VEGFA MMP9 MMP2 CDH1
153 deficiency anemia 10.1
154 thrombosis 10.1
155 placenta praevia 10.1
156 sarcoma 10.1
157 acute kidney failure 10.1
158 spindle cell sarcoma 10.1
159 placenta accreta 10.1
160 fibromatosis 10.1
161 posttransplant acute limbic encephalitis 10.1
162 bladder disease 10.1 NGF MMP9 CDH1
163 meningioma, familial 10.1 VEGFA PGR ESR1 CDH1
164 premenstrual tension 10.1 PRL PGR GNRH1
165 squamous cell carcinoma 10.1 VEGFA PTGS2 MMP2 CDH1
166 empty sella syndrome 10.0 PRL GNRH1
167 benign mesothelioma 10.0
168 colonic disease 10.0 VEGFA PTGS2 ESR1 CDH1
169 psammomatous meningioma 10.0 MMP9 MMP2 MME
170 oral cancer 10.0 PTGS2 MMP9 MMP2 CDH1
171 stomach disease 10.0 VEGFA PTGS2 MMP9 CDH1
172 cervical carcinosarcoma 10.0 PGR MME ESR1
173 thoracic benign neoplasm 10.0 PGR MME ESR1
174 breast benign neoplasm 10.0 PGR MME ESR1
175 parotitis 10.0 MMP9 MMP2
176 autoimmune disease 10.0
177 pulmonary alveolar microlithiasis 10.0
178 insulin-like growth factor i 10.0
179 mayer-rokitansky-kuster-hauser syndrome 10.0
180 body mass index quantitative trait locus 1 10.0
181 bacterial sepsis 10.0
182 fibroma 10.0
183 pain agnosia 10.0
184 iron deficiency anemia 10.0
185 low compliance bladder 10.0
186 eclampsia 10.0
187 thrombocytopenia 10.0
188 cystitis 10.0
189 constipation 10.0
190 clear cell adenocarcinoma 10.0
191 kidney disease 10.0
192 severe combined immunodeficiency 10.0
193 b-cell lymphoma 10.0
194 48,xyyy 10.0
195 back pain 10.0
196 unilateral aplasia of the mullerian ducts 10.0
197 septate uterus 10.0
198 pneumothorax 10.0 PGR MMP9 MMP2 GNRH1
199 male reproductive system disease 10.0 VEGFA GNRH1 CDH1
200 anovulation 10.0 PRL GNRH1 CYP19A1
201 hyperandrogenism 9.9 PRL GNRH1 CYP19A1
202 endometrial stromal nodule 9.9 PGR MME CYP19A1
203 premature ovarian failure 1 9.9 PRL GNRH1 CYP19A1
204 breast disease 9.9 VEGFA PRL PGR ESR1 CYP19A1
205 ovary epithelial cancer 9.9 VEGFA PGR MMP2 ESR1 CDH1
206 malignant ovarian surface epithelial-stromal neoplasm 9.9 VEGFA PGR MMP2 ESR1 CDH1
207 reproductive organ benign neoplasm 9.9 PGR GNRH1 ESR1 CYP19A1
208 extrahepatic bile duct adenocarcinoma 9.9 MME CDH1
209 cystic nephroma 9.9 PGR MME
210 gallbladder cancer 9.9 TIMP2 PTGS2 CDH1
211 pelvic varices 9.9 PRL GNRH1
212 cryptorchidism, unilateral or bilateral 9.8 HOXA10 GNRH1 CYP19A1
213 neurofibromatosis, type ii 9.8
214 hypercholesterolemia, familial, 1 9.8
215 nerve growth factor, alpha subunit 9.8
216 polycystic liver disease 1 with or without kidney cysts 9.8
217 pelvic organ prolapse 9.8
218 thrombophilia due to thrombin defect 9.8
219 renal hypodysplasia/aplasia 1 9.8
220 wilms tumor 1 9.8
221 anemia, hypochromic microcytic, with iron overload 1 9.8
222 hemangiopericytoma, malignant 9.8
223 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
224 homocysteinemia 9.8
225 cervical cancer 9.8
226 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
227 leukemia, acute lymphoblastic 3 9.8
228 hypochromic microcytic anemia 9.8
229 aphasia 9.8
230 marantic endocarditis 9.8
231 cardiac arrest 9.8
232 mastitis 9.8
233 hydronephrosis 9.8
234 pertussis 9.8
235 pyelonephritis 9.8
236 endosalpingiosis 9.8
237 mitral valve insufficiency 9.8
238 gestational diabetes 9.8
239 leukemia 9.8
240 acute kidney tubular necrosis 9.8
241 tuberous sclerosis 9.8
242 obstructive jaundice 9.8
243 interstitial cystitis 9.8
244 gonadal dysgenesis 9.8
245 chronic cystitis 9.8
246 intestinal perforation 9.8
247 dyspepsia 9.8
248 hyperpituitarism 9.8
249 thrombophilia 9.8
250 cervicitis 9.8
251 cystadenoma 9.8
252 perivascular epithelioid cell tumor 9.8
253 mesenchymoma 9.8
254 anuria 9.8
255 papillary adenocarcinoma 9.8
256 mesenchymal cell neoplasm 9.8
257 liposarcoma 9.8
258 placental insufficiency 9.8
259 carcinosarcoma 9.8
260 adenosquamous carcinoma 9.8
261 ureteral obstruction 9.8
262 urinary tract obstruction 9.8
263 endometrioid ovary carcinoma 9.8
264 hemolytic anemia 9.8
265 adenomatoid tumor 9.8
266 peritonitis 9.8
267 ileus 9.8
268 actinomycosis 9.8
269 placental abruption 9.8
270 hemometra 9.8
271 adenosarcoma of the uterus 9.8
272 asherman's syndrome 9.8
273 ovarian epithelial cancer 9.8
274 anoxia 9.8
275 bicornuate uterus 9.8
276 thrombotic microangiopathy 9.8
277 gastrointestinal system cancer 9.8 VEGFA PTGS2 MMP9 MMP2 CDH1
278 gastrointestinal system disease 9.8 VEGFA PTGS2 MMP9 MMP2 CDH1
279 large intestine cancer 9.8 VEGFA PTGS2 MMP9 MMP2 CDH1
280 lung cancer susceptibility 3 9.8 VEGFA PTGS2 MMP9 MMP2 CDH1
281 esophageal cancer 9.7 VEGFA PTGS2 MMP9 MMP2 CDH1
282 ewing sarcoma 9.7 VEGFA PTGS2 MMP9 MMP2 CDH1
283 male reproductive organ cancer 9.7 VEGFA MMP9 GNRH1 CDH1
284 ductal carcinoma in situ 9.7 PTGS2 PGR ESR1 CYP19A1 CDH1
285 gonadal disease 9.5 VEGFA PRL GNRH1 ESR1 CYP19A1
286 endocrine gland cancer 9.5 VEGFA MMP9 MMP2 ESR1 CYP19A1 CDH1
287 squamous cell carcinoma, head and neck 9.5 VEGFA TIMP2 PTGS2 MMP9 MMP2 CDH1
288 gastric adenocarcinoma 9.5 VEGFA TIMP2 PTGS2 MMP9 MMP2 CDH1
289 cholangiocarcinoma 9.4 PTGS2 MMP9 MME CDH1
290 renal cell carcinoma, nonpapillary 9.3 VEGFA MMP9 MMP2 MME CDH1
291 myocardial infarction 9.3 VEGFA PTGS2 MMP9 MMP2 MME ESR1
292 adamantinoma of long bones 9.1 VEGFA TIMP2 PTGS2 PGR MMP9 MMP2
293 ovarian disease 8.9 VEGFA PRL PGR NGF GNRH1 ESR1
294 prostate cancer 8.6 VEGFA PTGS2 MMP9 MMP2 GNRH1 ESR1
295 female reproductive system disease 8.4 VEGFA PRL PGR MMP9 MMP2 GNRH1
296 reproductive system disease 8.1 VEGFA PTGS2 PRL PGR MMP9 MMP2
297 breast cancer 7.8 VEGFA TIMP2 PTGS2 PRL PGR MMP9

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis

Symptoms & Phenotypes for Adenomyosis

Human phenotypes related to Adenomyosis:

32 (showing 3, show less)
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 32 HP:0001892
2 dysmenorrhea 32 HP:0100607
3 abnormality of the genitourinary system 32 HP:0000119

Symptoms via clinical synopsis from OMIM:

57
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM:

600458

MGI Mouse Phenotypes related to Adenomyosis:

46 (showing 17, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
2 behavior/neurological MP:0005386 10.27 CYP19A1 ESR1 MMP9 NGF OXTR PGR
3 cardiovascular system MP:0005385 10.26 CDH1 CYP19A1 ESR1 MMP2 MMP9 NGF
4 growth/size/body region MP:0005378 10.26 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2
5 immune system MP:0005387 10.26 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
6 endocrine/exocrine gland MP:0005379 10.24 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 OXTR
7 integument MP:0010771 10.23 CDH1 CYP19A1 ESR1 GNRH1 MME MMP9
8 hematopoietic system MP:0005397 10.16 CYP19A1 ESR1 GNRH1 MMP2 MMP9 PGR
9 digestive/alimentary MP:0005381 10.15 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
10 nervous system MP:0003631 10.1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9
11 muscle MP:0005369 10.06 CYP19A1 ESR1 MMP2 MMP9 NGF OXTR
12 neoplasm MP:0002006 10.02 CDH1 ESR1 GNRH1 MMP2 MMP9 PGR
13 liver/biliary system MP:0005370 9.98 CYP19A1 ESR1 GNRH1 MME PRL PTGS2
14 normal MP:0002873 9.9 CDH1 CYP19A1 ESR1 GNRH1 MMP2 NGF
15 no phenotypic analysis MP:0003012 9.8 CDH1 ESR1 NGF OXTR PGR PTGS2
16 reproductive system MP:0005389 9.7 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
17 skeleton MP:0005390 9.28 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 114, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Ibuprofen Approved Phase 4 15687-27-1 3672
4
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
5
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
6
Dienogest Approved Phase 4 65928-58-7
7
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
8
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
9
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
Norethindrone Approved Phase 4 68-22-4 6230
13
Buserelin Approved, Investigational Phase 4 57982-77-1
14
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
15
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
16
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
17 Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
18 Anti-Inflammatory Agents Phase 4
19 Analgesics Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Antipyretics Phase 4
24 Antirheumatic Agents Phase 4
25 Steroid Synthesis Inhibitors Phase 4
26 Estrogen Receptor Antagonists Phase 4
27 Estrogen Antagonists Phase 4
28 Aromatase Inhibitors Phase 4
29 Oxytocics Phase 4
30 Estrogens Phase 4
31 Hormones Phase 4
32 Hormone Antagonists Phase 4
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
34 Contraceptives, Oral, Combined Phase 4
35 Androgens Phase 4
36 Anabolic Agents Phase 4
37 Estradiol 3-benzoate Phase 4
38 Estradiol 17 beta-cypionate Phase 4
39 Triptorelin Pamoate Phase 4
40 Prolactin Release-Inhibiting Factors Phase 4
41 Norethindrone Acetate Phase 4
42 Antineoplastic Agents, Hormonal Phase 4
43 Contraceptives, Oral Phase 4
44 Contraceptive Agents, Male Phase 4
45 Progestins Phase 4
46 Fertility Agents Phase 4
47
Medroxyprogesterone Phase 4 520-85-4 10631
48
Levonorgestrel Approved, Investigational Phase 3 797-63-7, 17489-40-6 13109
49
Goserelin Approved Phase 2, Phase 3 65807-02-5, 1233494-97-7 47725 5311128
50
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
51
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
52 Ramosetron Investigational Phase 3 132036-88-5
53
Lactitol Investigational Phase 2, Phase 3 585-86-4, 585-88-6 493591
54 Serotonin Antagonists Phase 3
55 Serotonin Agents Phase 3
56 Micronutrients Phase 3
57 Nutrients Phase 3
58 Trace Elements Phase 3
59 Contraceptives, Postcoital Phase 2, Phase 3
60 Luteolytic Agents Phase 3
61
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
62
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
63
Quinagolide Approved, Investigational Phase 2 97805-50-0, 87056-78-8 105105
64 Hemostatics Phase 2
65 Cellulose, Oxidized Phase 2
66 Coagulants Phase 2
67 Dopamine Agents Phase 2
68 Dopamine agonists Phase 2
69
Bromocriptine Approved, Investigational Phase 1 25614-03-3 31101
70 Antiparkinson Agents Phase 1
71
Drospirenone Approved Early Phase 1 67392-87-4 68873
72
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
73
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
74
Povidone Approved 9003-39-8
75
Povidone-iodine Approved 25655-41-8
76
Ethinyl Estradiol Approved 57-63-6 5991
77
Iodine Approved, Investigational Early Phase 1 7553-56-2 807
78
Racepinephrine Approved 329-65-7 838
79
Epinephrine Approved, Vet_approved 51-43-4 5816
80
Bupivacaine Approved, Investigational 2180-92-9, 38396-39-3 2474
81
Gestodene Investigational 60282-87-3 3033968
82 Diuretics, Potassium Sparing Early Phase 1
83 Natriuretic Agents Early Phase 1
84 Mineralocorticoid Receptor Antagonists Early Phase 1
85 diuretics Early Phase 1
86 Mineralocorticoids Early Phase 1
87
Ethylene Early Phase 1 74-85-1 6325
88 Drospirenone and ethinyl estradiol combination Early Phase 1
89 Gastrointestinal Agents
90 Antiemetics
91 HIV Protease Inhibitors
92
protease inhibitors
93 glucocorticoids
94 BB 1101
95 cadexomer iodine
96 Neurotransmitter Agents
97 Femovan
98 Autonomic Agents
99 Peripheral Nervous System Agents
100 Pharmaceutical Solutions Early Phase 1
101 Sympathomimetics
102 Anesthetics, Local
103 Adrenergic Agonists
104 Respiratory System Agents
105 Adrenergic beta-Agonists
106 Adrenergic alpha-Agonists
107 Epinephryl borate
108 Central Nervous System Depressants
109 Mydriatics
110 Anti-Asthmatic Agents
111 Adrenergic Agents
112 Anesthetics
113 Vasoconstrictor Agents
114 Bronchodilator Agents

Interventional clinical trials:

(showing 78, show less)
# Name Status NCT ID Phase Drugs
1 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
2 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
3 Use of Oxytocin in MRI-HIFU Treatment Enrolling by invitation NCT03937401 Phase 4 Oxytocin
4 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Not yet recruiting NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
5 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
6 Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized Terminated NCT01776203 Phase 4 Medroxyprogesterone 17-Acetate
7 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
8 Uterine Artery Doppler and Three Dimensional Power Doppler in the Diagnosis of Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
9 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
10 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
11 Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study Unknown status NCT02437175 Phase 3
12 Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial Unknown status NCT01125488 Phase 3 GnRH agonist (triptorelin)
13 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
14 Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
15 Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
16 Mifepristone Versus Placebo to Treat Adenomyosis: a Double-blind, Multicentre,Randomized Clinical Trial Recruiting NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
17 Effect of Elastic Abdominal Binder on Pain and Functional Recovery After Open Abdominal Surgery for Benign Gynecologic Conditions: a Randomized Controlled Trial Recruiting NCT03820115 Phase 3
18 Phase III Trial to Assess Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI Outcomes in Infertile Women Presenting With Adenomyosis. Not yet recruiting NCT03940807 Phase 3 11.25mg GnRH agonist;0.1 mg GnRH agonist;25 µg transdermal oestradiol
19 Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis Unknown status NCT02587000 Phase 2 Ulipristal acetate;Placebo
20 Surgicel® Versus Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding (HMB): Randomised Controlled Trial Unknown status NCT03176992 Phase 2 SURGICEL®
21 Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial Completed NCT01601366 Phase 2 Combined oral contraceptives
22 Tactile Versus Hysteroscopic Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
23 A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis Recruiting NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
24 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
25 Vaginal Bromocriptine for the Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
26 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
27 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
28 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
29 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
30 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis : A Preliminary Study Unknown status NCT01259180
31 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Unknown status NCT03006406 Long term GnRH-a (3.75mg)
32 Prospective Cohort Study to Compare to 2-channel and Multiple Channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
33 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone Unknown status NCT00928044
34 "Estudio de Histerosalpingografía Por Resonancia Magnética Para la evaluación Integral de la Paciente infértil." Unknown status NCT02398630
35 The Effect in Term of Ovarian Reserve Modification of Adding Prophylactic Bilateral Salpingectomy (PBS) to TLH for Preventing Ovarian Cancer Unknown status NCT02086344
36 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
37 Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Can Be Useful Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
38 The Diagnostic Accuracy of Hysteroscopic Endomyometrial Biopsy in Adenomyosis Completed NCT02340533
39 Cohort Study of Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648
40 Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part I Completed NCT02201719
41 Can the Effect of Levonorgestrel Intrauterine System for Treatment of Adenomyosis be Predicted at Baseline Visit? Completed NCT03104309
42 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
43 Short and Long Term Outcomes of Uterine Artery Embolization. Completed NCT00354471
44 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy: a Randomized, Single-Blinded Study Comparing the Efficacy to the Routine Procedure Completed NCT01806012
45 The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization Completed NCT02056717 Dexamethasone;Normal saline
46 Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery Completed NCT01463462
47 A Multicenter Observational Study of Diphereline 3.75 mg Treatment Effectiveness in Russian Women Suffering From Internal Genital Endometriosis Completed NCT03586063
48 Randomized Trial of Laparoscopic Versus Abdominal Hysterectomy for Benign Indications and Impact on Surgical Success Completed NCT01793584
49 Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial Completed NCT01628432
50 Bladder Endometriosis: Evaluation in MRI of the Involvement of the Posterior Inferior Wall Completed NCT03906760
51 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? A Randomized Controlled Trial Comparing 3D Laparoscopy Versus Standard Laparoscopy Completed NCT02192606
52 Magnetic Resonance Imaging Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility Completed NCT02108665
53 Sonohysterography and 3D Ultrasonography Versus Diagnostic Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501
54 AMH Levels Change During Treatment With GnRh Agonist: A Prospective Observational Study. Completed NCT02086279 GnRH analogue
55 A Randomised Control Trial of Three-dimensional Versus Two-dimensional Ultrasound Guided Embryo Transfer in Women Undergoing Artificial Reproductive Technology Treatment Completed NCT02413697
56 Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy Completed NCT02281487
57 A Study of Cooperative Network of Diagnosis and Treatment of Uterine Adenomyosis. Recruiting NCT03230994
58 A Multi-omics Study on the Tumorigenesis of Adenomyosis Recruiting NCT03742843
59 A Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis Recruiting NCT04010487
60 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms and Gastrointestinal Symptoms Recruiting NCT02495311
61 Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri Recruiting NCT03890042 Dienogest group;Gestodene-Ethinyl Estradiol
62 Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Recruiting NCT02914704
63 Development and Validation of the Endometriosis Health Profile-30 Traditional Chinese (Hong Kong) Version in Endometriosis and Adenomyosis Recruiting NCT03302468
64 Role of Abdominal Drainage for Laparoscopic Cholecystectomy a Prospective Randomised Study Recruiting NCT03909360
65 Intraoperative Use of Intravenous Indocyanine Green (ICG) to Assess Ovarian Perfusion Using Infrared Imaging: A Feasibility Pilot Study Recruiting NCT03927651 Early Phase 1 ICG
66 A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Paracervical Block Before Total Laparoscopic Hysterectomy for Postoperative Pain Control (PALAPA): Recruiting NCT03792009 5% bupivacaine;Normal saline
67 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Recruiting NCT03121560
68 The Accuracy of Three-dimensional Power Doppler Ultrasound in the Diagnosis of Endometrial Lesions in Patients With Postmenopausal Bleeding Compared With the Endometrial Histopathology. Recruiting NCT03543592
69 Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnosis, Part 2 Active, not recruiting NCT02197923
70 Therapeutic Efficacy of High-intensity Focused Ultrasound in the Treatment of Uterine Adenomyosis Enrolling by invitation NCT02954757
71 Characterisation of Tissue Stiffness to Improve the Diagnosis and Management of Uterine Fibroids Enrolling by invitation NCT03369600
72 Adenomyosis: Genomic Mechanisms and Biological Response Not yet recruiting NCT03428854 LNG-IUS
73 A Randomized, Controlled, Multi-Center Study to Assess the Safety and Efficacy of Actamax™ Adhesion Barrier in Women Undergoing Laparoscopic Abdominopelvic Surgery With a Myomectomy Followed by Second Look Laparoscopy (SLL) Not yet recruiting NCT03450421
74 Endometrial Evaluation in Cases of Postmenopausal Bleeding Using Three Dimensional Ultrasound , Power Doppler Angiography and Office Hysteroscopy in Correlation to Pathological Findings . Not yet recruiting NCT03847415
75 Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer Not yet recruiting NCT03762837
76 Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part III Suspended NCT02197936
77 Diagnostic Accuracy of Ultrasound for Adenomyosis, Development of Scoring System and Correlation With Various Pelvic Pathologies: a Prospective Study. Terminated NCT03120078
78 Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain Withdrawn NCT02160483

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Genetic Tests for Adenomyosis

Anatomical Context for Adenomyosis

MalaCards organs/tissues related to Adenomyosis:

41
Uterus, Pituitary, Breast, Endothelial, Smooth Muscle, Testes, Cervix

Publications for Adenomyosis

Articles related to Adenomyosis:

(showing 2491, show less)
# Title Authors PMID Year
1
Adenomyosis: evidence for genetic cause. 38 8
7762596 1995
2
The elusive adenomyosis of the uterus. Its historical past and its present state of recognition. 38 8
13890115 1962
3
Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system. 38
31194884 2019
4
Expression of annexin A2 in adenomyosis and dysmenorrhea. 38
31183557 2019
5
Adenomyosis As a Confounder to Accurate Endometrial Cancer Staging. 38
31375175 2019
6
Expression of Nerve Injury-Induced Protein1 (Ninj1) in Endometriosis. 38
30326781 2019
7
Biological differences between intrinsic and extrinsic adenomyosis with coexisting deep infiltrating endometriosis. 38
31160242 2019
8
A critical review of recent advances in the diagnosis, classification, and management of uterine adenomyosis. 38
31192829 2019
9
Is High-Intensity Focused Ultrasound (HIFU) effective for the treatment of Adenomyosis? A systematic review and meta-analysis. 38
31377454 2019
10
The expression of Bcl-2 in adenomyosis and its effect on proliferation, migration, and apoptosis of endometrial stromal cells. 38
31174926 2019
11
The outcome of fertility sparing and non-fertility sparing surgery for the treatment of adenomyosis. A systematic review and meta-analysis. 38
31398415 2019
12
Inhibition of formin like 2 promotes the transition of ectopic endometrial stromal cells to epithelial cells in adenomyosis through a MET-like process. 38
31175924 2019
13
Genetic Variants in the Nucleotide Excision Repair Genes are Associated with the Risk of Developing Endometriosis. 38
31373346 2019
14
Advanced fibroid study: paying homage to John Sampson. 38
31204258 2019
15
Decreased ADAMTS-1, -9 and -20 levels in women with endometrial polyps: a possible link between extracellular matrix proteases and endometrial pathologies. 38
31010360 2019
16
Persistence of Symptoms After Total vs Supracervical Hysterectomy in Women with Histopathological Diagnosis of Adenomyosis. 38
30205164 2019
17
The Association of Sonographic Evidence of Adenomyosis with Severe Endometriosis and Gene Expression in Eutopic Endometrium. 38
30273686 2019
18
The factors contributing to the total radiation exposure of patients during uterine artery embolisation. 38
31332961 2019
19
Effect of pretreatment with a levonorgestrel-releasing intrauterine system on IVF and vitrified-warmed embryo transfer outcomes in women with adenomyosis. 38
31109894 2019
20
Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: a systematic review and meta-analysis. 38
31318420 2019
21
Diagnosing adenomyosis with MRI: a prospective study revisiting the junctional zone thickness cutoff of 12 mm as a diagnostic marker. 38
31264010 2019
22
The effect of transcervical endometrial resection on clinical symptoms related to intrinsic adenomyosis and junctional zone changes. 38
31404400 2019
23
Ultrasound assessment of uterine morphology in menorrhagia: case control study. 38
31352859 2019
24
Preserving Fertility by Treating the 3 Compartments: Laparoscopic Approach to Deep Infiltrating Endometriosis. 38
30195079 2019
25
Transition from multiport to single-site surgery: A single institution experience in robotic supracervical hysterectomy for benign gynecological diseases. 38
31307743 2019
26
Bladder Endometriosis: Management by Cystoscopic and Laparoscopic Approaches. 38
30278234 2019
27
Histological evaluation of the prevalence of adenomyosis, myomas and of their concomitance. 38
30486633 2019
28
Transmembrane G protein-coupled receptor 30 gene polymorphisms and uterine adenomyosis in Korean women. 38
30626229 2019
29
Current facts constituting an understanding of the nature of adenomyosis. 38
30085434 2019
30
Hysteroscopic Treatment of Symptomatic Adenomyoma 38
31245966 2019
31
Endometrial Carcinoma: Grossing, Frozen Section Evaluation, Staging, and Sentinel Lymph Node Evaluation. 38
31097107 2019
32
Decreased expression of cell polarity protein Scribble correlated with altered subcellular localization of the Crumbs homologue 3 protein in human adenomyotic endometrial cells. 38
30912223 2019
33
The ectonucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in human endometrium: a novel marker of basal stroma and mesenchymal stem cells. 38
31123897 2019
34
Gynecological associated disorders and management. 38
31144734 2019
35
Surgical Management of Cesarean Scar Defect: The Hysteroscopic-Assisted Robotic Single-Site Technique. 38
31220602 2019
36
Association between disease extent and pain symptoms in patients with deep infiltrating endometriosis. 38
31378689 2019
37
Evaluation of the routine use of pelvic MRI in women presenting with symptomatic uterine fibroids: When is pelvic MRI useful? 38
30614145 2019
38
Sonographic classification and reporting system for diagnosing adenomyosis. 38
29790217 2019
39
The Autonomic Innervation and Uterine Telocyte Interplay in Leiomyoma Formation. 38
30841718 2019
40
Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. 38
30828808 2019
41
Two- and three-dimensional transvaginal ultrasonography for diagnosis of adenomyosis of the inner myometrium. 38
30792048 2019
42
Robot assisted radical nephrectomy + hysterectomy and specimen retrieval per vaginum (NOSE). 38
30735334 2019
43
Transvaginal Natural Orifice Transluminal Endoscopic Surgery Hysterectomy Aided by Transcervical Instrumental Uterine Manipulation. 38
31100341 2019
44
miR-21 reverses impaired decidualization through modulation of KLF12 and NR4A1 expression in human endometrial stromal cells†. 38
30772912 2019
45
Ultrasound of Pelvic Pain in the Nonpregnant Woman. 38
30928080 2019
46
A comparison of surgical outcomes between robot and laparoscopy-assisted adenomyomectomy. 38
31045825 2019
47
Elasticity of adenomyosis is increased after GnRHa therapy and is associated with spontaneous pregnancy in infertile patents. 38
31067498 2019
48
Biological differences between focal and diffuse adenomyosis and response to hormonal treatment. 38
30850322 2019
49
[Feasibility and safety of MRgFUS ablation for uterine fibroids and adenomyosis: a preliminary study]. 38
31006218 2019
50
[Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis]. 38
31309749 2019
51
Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy. 38
31030317 2019
52
Association between Preoperative Adenomyosis Detection Rate during Pelvic Ultrasonography and the Specialty of the Reading Physician. 38
31004795 2019
53
MR findings of uterine PEComa in patients with tuberous sclerosis: report of two cases. 38
30778737 2019
54
Preliminary functional inquiry of lncRNA ENST00000433673 in embryo implantation using bioinformatics analysis. 38
30649983 2019
55
Abnormal Uterine Bleeding in Premenopausal Women. 38
30932448 2019
56
Uterine artery embolisation in women with symptomatic adenomyosis. 38
31036387 2019
57
[Progress on medical treatment in the management of adenomyosis]. 38
31309751 2019
58
Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity. 38
30929720 2019
59
[Stratified treatment and management of adenomyosis]. 38
31309748 2019
60
Effects of adenomyosis on obstetric outcomes. 38
30318871 2019
61
Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis. 38
30675965 2019
62
Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: A pilot study. 38
31025313 2019
63
[The second generation endometrial ablation (NovaSure) improves efficacy of levonorgestrel-releasing intrauterine system in management of adenomyosis]. 38
31309750 2019
64
Impact of Coexisting Uterine Adenomyosis on the Survival Outcome of Patients with Endometrial Cancer: A Retrospective Cohort Study 38
31030493 2019
65
Incidental Detection of Endometriosis with 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Patient with Cervical Intraepithelial Neoplasia and Adenomyosis. 38
31040534 2019
66
Unusual case of intra-abdominal candidiasis following laparoscopic hysterectomy. 38
30948411 2019
67
Artificial Neural Network Analysis of Spontaneous Preterm Labor and Birth and Its Major Determinants. 38
31020816 2019
68
Tumor Budding is a Valuable Diagnostic Parameter in Prediction of Disease Progression of Endometrial Endometrioid Carcinoma. 38
30604272 2019
69
Ultrasonographic 'soft' markers for the detection of rectosigmoid endometriosis. 38
30977185 2019
70
Hemodynamic forces enhance decidualization via endothelial-derived prostaglandin E2 and prostacyclin in a microfluidic model of the human endometrium. 38
30789661 2019
71
Intrauterine cystic adenomyosis: Report of two cases. 38
30863769 2019
72
Adenomyosis: genetics of estrogen metabolism. 38
30878995 2019
73
Inter-rater agreement in the diagnosis of adenomyosis by 2- and 3-dimensional transvaginal ultrasonography. 38
30182497 2019
74
What if deep endometriotic nodules and uterine adenomyosis were actually two forms of the same disease? 38
30722943 2019
75
Clinical efficacy of adenomyomectomy using "H" type incision combined with Mirena in the treatment of adenomyosis. 38
30882624 2019
76
Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis. 38
30832539 2019
77
Endometriosis of the Appendix: When to Predict and How to Manage-A Multivariate Analysis of 1935 Endometriosis Cases. 38
30849476 2019
78
Risk of preterm birth, low birthweight and small-for-gestational-age infants in pregnancies with adenomyosis: A cohort study of the Japan Environment and Children's Study. 38
30367455 2019
79
The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. 38
29871559 2019
80
Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids. 38
30382803 2019
81
Endometriosis treatment with shock waves: A novel approach. 38
30798904 2019
82
Accessory cavitated uterine mass: MRI features and surgical correlations of a rare but under-recognised entity. 38
30159623 2019
83
Keeping an Eye on Perimenopausal and Postmenopausal Endometriosis. 38
30870972 2019
84
The Disease Phenotype of Adenomyosis-Affected Women Correlates With Specific Serum Cytokine Profiles. 38
30518300 2019
85
Diffuse massive adenomyosis and infertility. Is it possible to treat this condition? 38
30753160 2019
86
Evaluation and Management of Abnormal Uterine Bleeding. 38
30711128 2019
87
Transvaginal Ultrasound Vibro-elastography for Measuring Uterine Viscoelasticity: A Phantom Study. 38
30467032 2019
88
Polypoid Adenomyoma of the Uterus. 38
31016072 2019
89
Two- and three-dimensional ultrasonographic features related to histopathology of the uterine endometrial-myometrial junctional zone. 38
30317553 2019
90
Upregulation of long noncoding RNA TUG1 by EGR1 promotes adenomyotic epithelial cell migration and invasion through recruiting EZH2 and suppressing TIMP2. 38
30593723 2019
91
In Vivo Adenomyosis Tissue Sampling Using a Transvaginal Ultrasound-guided Core Biopsy Technique for Research Purposes: Safety, Feasibility, and Effectiveness. 38
30738919 2019
92
Pathogenesis of endometriosis: the genetic/epigenetic theory. 38
30527836 2019
93
Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. 38
30009497 2019
94
Malignant transformation of adenomyosis: literature review and meta-analysis. 38
30519753 2019
95
Recent advances in understanding and managing adenomyosis. 38
30918629 2019
96
Uterine adenomyosis: pathogenesis, diagnostics, symptomatology and treatment. 38
31324117 2019
97
Correlation of LOX‑5 and COX‑2 expression with inflammatory pathology and clinical features of adenomyosis. 38
30387822 2019
98
Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis. 38
30800671 2019
99
Menstruation-related disseminated intravascular coagulation in an adenomyosis patient: case report and review of the literature. 38
30044152 2019
100
Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis. 38
30994010 2019
101
Erratum: The rate of euploid miscarriage is increased in the setting of adenomyosis. 38
30895972 2019
102
Does presence of adenomyosis affect reproductive outcome in IVF cycles? A retrospective analysis of 973 patients. 38
30446308 2019
103
Clinical and Ultrasound Characteristics of the Microcystic Elongated and Fragmented (MELF) Pattern in Endometrial Cancer According to the International Endometrial Tumor Analysis (IETA) criteria. 38
30640693 2019
104
Clinical anatomy of pelvic pain in women: A Gynecological Perspective. 38
30390350 2019
105
Association between Morphological Patterns of Myometrial Invasion and Cancer Stem Cell Markers in Endometrial Endometrioid Carcinoma. 38
28990139 2019
106
Adverse obstetrical outcomes for women with endometriosis and adenomyosis: A large cohort of the Japan Environment and Children's Study. 38
31374085 2019
107
Comparisons of the efficacy and recurrence of adenomyomectomy for severe uterine diffuse adenomyosis via laparotomy versus laparoscopy: a long-term result in a single institution. 38
31303783 2019
108
Adenomyosis:A Clinico-pathological Study. 38
30924123 2019
109
Transvaginal Ultrasound Shear Wave Elastography for the Evaluation of Benign Uterine Pathologies: A Prospective Pilot Study. 38
29732594 2019
110
Connective tissue growth factor mediates transforming growth factor β-induced collagen expression in human endometrial stromal cells. 38
30695033 2019
111
FAK regulates epithelial‑mesenchymal transition in adenomyosis. 38
30365102 2018
112
[A STUDY OF UTERINE HEMODYNAMICS USING THREE-DIMENSIONAL POWER DOPPLER SONOGRAPHY IN PATIENTS WITH ADENOMYOSIS]. 38
30702064 2018
113
Clinical Usefulness of the Microbubble Contrast Agent SonoVue in Enhancing the Effects of High-Intensity Focused Ultrasound for the Treatment of Adenomyosis. 38
29689636 2018
114
Effect of pre-treatment with gonadotropin-releasing hormone analogue GnRH-α on high-intensity focussed ultrasound ablation for diffuse adenomyosis: a preliminary study. 38
29447020 2018
115
RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis. 38
30387365 2018
116
Cerebral infarcts associated with adenomyosis: a rare risk factor for stroke in middle-aged women: a case series. 38
30567506 2018
117
Catechol-O-methyltransferase 158G/A polymorphism and endometriosis/adenomyosis susceptibility: A meta-analysis in the Chinese population. 38
30539833 2018
118
Müllerianosis, Endocervicosis, and Endosalpingiosis of the Urinary Tract: A Literature Review. 38
29739266 2018
119
Assessment of ovarian reserve after cystectomy versus 'one-step' laser vaporization in the treatment of ovarian endometrioma: a small randomized clinical trial. 38
30299482 2018
120
P21-Activated Kinase 1 Overactivates in Eutopic Endometrium of Adenomyosis. 38
30453819 2018
121
Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis. 38
29266553 2018
122
Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. 38
29626678 2018
123
Predisposing factors for predicting the therapeutic response of adenomyosis after uterine artery embolization: serum CA125 levels and accompanying endometriosis. 38
30373724 2018
124
Elusive adenomyosis: a plea for an international classification system to allow artificial intelligence approaches to reset our clinical management. 38
30396546 2018
125
A sonographic classification of adenomyosis: interobserver reproducibility in the evaluation of type and degree of the myometrial involvement. 38
30396560 2018
126
Endometrial Changes in Surgical Specimens of Perimenopausal Patients Treated With Ulipristal Acetate for Uterine Leiomyomas. 38
28914672 2018
127
Cerebral infarction associated with benign mucin-producing adenomyosis: report of two cases. 38
30286732 2018
128
OC01: Transvaginal ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis. 38
30284361 2018
129
Development of a clinical prediction model for diagnosing adenomyosis. 38
30316443 2018
130
A new era in diagnosing adenomyosis is coming. 38
30316431 2018
131
Clinical Manifestations of Adenomyosis Patients with or without Coexisting Endometriosis. 38
30334538 2018
132
Endometrial receptivity and adenomyosis. 38
30342640 2018
133
Window of Implantation is Significantly Displaced in Patients with Adenomyosis with Previous Implantation Failure as Determined by Endometrial Receptivity Assay. 38
30787520 2018
134
[Effect of gonadotropin-releasing hormone agonist used before surgery on natural pregnancy rates in patients with ovarian endometriomas]. 38
30369124 2018
135
Gallbladder Polyps: Real or Imagined? 38
30747692 2018
136
Transient uterine contractions as a potential pathology mimic on premenopausal pelvic MRI and the role of routine repeat T2 sagittal images to improve observer confidence. 38
29917321 2018
137
[Degree of fibrosis of adenomyotic myometrium and its relationship with dysmenorrhea]. 38
30369125 2018
138
High Signal in Bone Marrow on Diffusion-Weighted Imaging of Female Pelvis: Correlation With Anemia and Fibroid-Associated Symptoms. 38
29504179 2018
139
Adenomyosis: A Sonographic Diagnosis. 38
30207945 2018
140
Treatment of Adenomyosis with Subcutaneous Etonogestrel Implants: A Clinical Observational Study in 17 Patients. 38
30171680 2018
141
Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis. 38
29998482 2018
142
Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? 38
29893860 2018
143
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science. 38
29962279 2018
144
Correlation between Adenomyosis and Endometrial cancer: 6-year experience of a single center. 38
31191849 2018
145
Pain is an Independent Risk Factor for Failed Global Endometrial Ablation. 38
29374620 2018
146
Laparoendoscopic Single-Site Supracervical Hysterectomy with Manual Morcellation: A Retrospective Study. 38
29501811 2018
147
Extrauterine adenomyoma: a review of the literature. 38
29940416 2018
148
Incarceration of early gravid uterus with adenomyosis and myoma: report of two patients managed with uterine reduction. 38
30254999 2018
149
Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. 38
29753309 2018
150
Endometrial CRH and implantation: from bench to bedside. 38
29916119 2018
151
Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis. 38
30087549 2018
152
Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. 38
29447009 2018
153
Coexistence of adenomyosis, adenocarcinoma, endometrial and myometrial lesions in resected uterine specimens. 38
30101029 2018
154
"Recurrent multiple cerebral infarctions related to the progression of adenomyosis: a case report". 38
30129425 2018
155
Thermal bowel injury after ultrasound-guided high-intensity focused ultrasound treatment of uterine adenomyosis. 38
29154472 2018
156
Prevalence of abnormal uterine bleeding according to new International Federation of Gynecology and Obstetrics classification in Chinese women of reproductive age: A cross-sectional study. 38
30075511 2018
157
Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes. 38
29299762 2018
158
Long-term dienogest administration in patients with symptomatic adenomyosis. 38
29845696 2018
159
Ultrasound diagnosis of endometriosis and adenomyosis: State of the art. 38
29506961 2018
160
The Risk of Preterm Births Among Pregnant Women With Adenomyosis. 38
29363150 2018
161
Minimally invasive treatment of adenomyosis. 38
29555380 2018
162
Multiple Synchronous Lesions in the Genital Tract of a Female: A Rare Combination with Unrelated Histogenesis. 38
30202764 2018
163
Endometrial L-selectin ligand is downregulated in the mid-secretory phase during the menstrual cycle in women with adenomyosis. 38
30122569 2018
164
Accuracy and Reproducibility of Sonoelastography for the Assessment of Fibroids and Adenomyosis, with Magnetic Resonance Imaging as Reference Standard. 38
29784438 2018
165
Evaluation of NovaSure® global endometrial ablation in symptomatic adenomyosis: A longitudinal study with a 36 month follow-up. 38
29886317 2018
166
A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. 38
29344938 2018
167
Adenomyosis and IVF/ICSI treatment: clinical considerations and recommendations. 38
30063420 2018
168
Conservative surgery of uterine adenomyosis via laparoscopic versus laparotomic approach in a single institution. 38
29845687 2018
169
Efficacy of Hormonal Therapies for Decreasing Uterine Volume in Patients with Adenomyosis. 38
30254953 2018
170
Anterior Focal Adenomyosis and Bladder Deep Infiltrating Endometriosis: Is There a Link? 38
29432902 2018
171
Association of Endometriosis and Adenomyosis: Vast Literature but Scant Conclusive Data. 38
29581073 2018
172
Value of in vitro acoustic radiation force impulse application on uterine adenomyosis. 38
29177930 2018
173
Isolated Ovarian Endometrioma: A History Between Myth and Reality. 38
29353008 2018
174
The significance and evolution of menstruation. 38
29530426 2018
175
Magnetic resonance imaging of degeneration of uterine adenomyosis during pregnancy and post-partum period. 38
29516583 2018
176
Experience of Symptoms and Disease Impact in Patients with Adenomyosis. 38
29197944 2018
177
Adenomyosis: fertility and obstetric outcome. A comprehensive literature review. 38
29115118 2018
178
Comparison of UpholdTM Vaginal Mesh Procedure with Hysterectomy or Uterine Preservation for the Treatment of Pelvic Organ Prolapse. 38
29930249 2018
179
Intravenous leiomyomatosis of the uterus: A clinicopathologic analysis of 13 cases with an emphasis on histogenesis. 38
29699902 2018
180
A case report of ovotesticular disorder of sex development (OT-DSD) in a baboon (Papio spp.) and a brief review of the non-human primate literature. 38
29504143 2018
181
Effects of pelvic endometriosis and adenomyosis on ciliary beat frequency and muscular contractions in the human fallopian tube. 38